The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
PHASE4
Olanzapine is currently marketed for the treatment of schizophrenia and acu...
A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects
PHASE1
Approximately 60 obese, but otherwise healthy, subjects will be assessed in...
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
PHASE2
This study will examine the safety, tolerability, and body weight effect of...